Bristol Myers Squibb & Co (NYSE: BMY) said that its Q2 revenues of $11.23 billion declined 6% Y/Y, or 5% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line products and our new product portfolio.

Related Keywords

Canada , Bristol Myers , Bristol Myers Squibb Co , Bristol Myers Squibb , Patient Assistance Foundation , Patient Assistance ,